Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe
 

Discontinuing Immunotherapy Because of Adverse Effects May Not Compromise Efficacy

TOP - May 2017, Vol 10, No 2 - Side-Effects Management, Side-Effects Management
Phoebe Starr

Orlando, FL—The current practice in the treatment of advanced kidney cancer and some other cancers is to continue treatment with immune checkpoint inhibitors until disease progression, and sometimes even longer. However, the results of a new, preliminary trial call this practice into question by suggesting that the benefits of immunotherapy can continue in some patients, even if treatment is stopped prematurely.

The study, presented at the 2017 Genitourinary Cancers Symposium, included an international cohort of 19 patients with metastatic renal-cell carcinoma who responded to initial treatment with nivolumab-based immunotherapy, but stopped treatment because of immune-related adverse effects.

Among these patients, 42% had a durable response, defined as time not receiving therapy for ≥6 months, according to Rana R. McKay, MD, Medical Oncologist and Assistant Professor of Medicine, University of California San Diego School of Medicine, La Jolla.

Although the persistence of response after discontinuing immune checkpoint inhibitor therapy has been reported anecdotally, this is the first systematic study to evaluate the outcomes of patients with metastatic renal-cell carcinoma who stop anti–PD-1/PD-L1 immune checkpoint inhibitor therapy because of immune-related side effects, Dr McKay and colleagues noted.

“In medicine, we are constantly balancing the benefits and risks of any given treatment. This is a small study, and our findings need to be validated in a larger group of patients, but it underscores that, in some cases, immunotherapy can have lasting benefits even after treatment discontinuation,” Dr McKay stated.

Patients had received nivolumab either as monotherapy (63%) or in combination with other systemic treatments (37%). The median time receiving immunotherapy was 5.5 months. All 19 patients discontinued treatment because of immune-related adverse effects, which included joint pain, rash, eye problems, diarrhea, and inflammation of the pituitary gland, muscle, heart, liver, pancreas, kidney, or lung.

Steroids were administered to 84% of patients, and additional immunosuppressive agents were required for 11%. More than half of the group had ongoing toxicity at the time of the analysis.

In 3 (16%) patients, the tumor progressed immediately after stopping treatment, but 8 (42%) patients had a continued (durable) response ≥6 months posttreatment. Patients with a durable response spent a median of 11 months receiving treatment and 20 months not receiving treatment, Dr McKay reported. The remaining 8 (42%) patients did not receive treatment for 4 to 6 months, or had follow-up for <6 months.

“We demonstrated that responders to anti–PD-1/PD-L1 agents can have persistent clinical benefit despite treatment discontinuation for immune-related adverse events,” Dr McKay said.

She and her co-investigators hope to include more patients in this analysis so that they can identify the clinical characteristics associated with a durable response to immunotherapy.

A prospective phase 2 trial called OMNIVORE (Optimized Management of Nivolumab Based on Response) is planned to further explore the efficacy of immunotherapy after treatment discontinuation in patients who respond to treatment.

“This study is welcome news for patients who are unable to continue immunotherapy as a result of adverse effects. It is reassuring to see that some patients may continue to benefit from immunotherapy, even if they need to discontinue it,” said press cast moderator Sumanta Pal, MD, Co-Director, City of Hope Kidney Cancer Program, Duarte, CA.

Dr Pal emphasized that although the “unintended consequences of a reinvigorated immune response [ie, immune-related adverse events] can be serious,” patients with these side effects “can still have tangible benefit from these drugs.”

“More broadly, these findings call into question the current standard of continuous treatment with immunotherapy, although longer-term follow-up of patients is needed,” Dr Pal said.

Related Items
Sitravatinib, Novel TKI, plus Nivolumab Elicits Good Responses in Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2020, Vol 13, No 3 published on May 21, 2020 in Emerging Therapies
First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2020, Vol 13, No 3 published on May 21, 2020 in Emerging Therapies
Real-World Healthcare Utilization and Costs Support Broader Use of CAR T-Cell Therapy
Phoebe Starr
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in Value-Based Care
Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy By
Phoebe Starr
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in ASH 2019 Highlights
Improving Access to Genetic Cancer Screening in a Medically Underserved Community
Phoebe Starr
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in ACCC
Ceritinib Effective in Treating Brain Metastases in NSCLC
Phoebe Starr
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in Lung Cancer
Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations
Phoebe Starr
Web Exclusives published on February 24, 2020 in ESMO
Osimertinib Superior TKI as First-Line Treatment of Advanced NSCLC with EGFR Mutation
Phoebe Starr
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Lung Cancer
Nivolumab plus Ipilimumab Combination Improves Survival in Patients with Metastatic NSCLC
Phoebe Starr
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Lung Cancer
Olaparib Improves Outcomes in Metastatic Prostate Cancer with Gene Mutations
Phoebe Starr
TOP - January 2020, Vol 13, No 1 published on January 10, 2020
Last modified: April 27, 2020